Key Takeaways:
argenx's Vyvgart Hytrulo met its primary endpoint in a Phase III autoimmune myositis trial, posting a 15.4-point improvement in Total Improvement Score at Week 52 versus placebo, sending shares up 16% to $990.15.
"These are the first Phase 3 results to show that precision targeting of FcRn with efgartigimod can deliver meaningful benefit in this disease," Luc Truyen, chief medical officer at argenx, said.
The ALKIVIA study enrolled 264 patients with immune-mediated necrotizing myopathy (IMNM) or dermatomyositis (DM) on background therapy. In the combined population, efgartigimod produced a mean TIS of 47.95 versus 32.56 for placebo (p=0.0011), with separation from placebo emerging by Week 4 and holding through the full 52-week treatment period even as steroids were tapered. In a prespecified subtype analysis, IMNM patients achieved a 14.8-point advantage (p=0.0048) — the first Phase III study to show statistically significant improvement in a subtype with no approved therapy. DM patients posted a similar 14.5-point benefit, though the smaller cohort did not reach statistical significance (p=0.1093).
The results expand Vyvgart Hytrulo's addressable market into a disease affecting roughly 100,000 people in the U.S., including about 20,000 with IMNM and 40,000 with DM, most of whom currently rely on corticosteroids and broad immunosuppressants. The drug, a subcutaneous formulation of the FcRn-blocking antibody fragment efgartigimod, is already approved for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Vyvgart franchise extends into a new indication
The ALKIVIA outcome removes a key binary clinical risk for argenx and supports its strategy of expanding efgartigimod across autoimmune diseases. All six core set measures of TIS favored efgartigimod over placebo, spanning muscle strength, physical function and disease activity beyond the muscle, with skin disease improvement also observed in DM patients. Efgartigimod was well tolerated, with a safety profile consistent with prior studies.
Analysts responded by raising price targets. One update lifted the 12-month target from $940 to $1,202, while consensus targets now cluster between roughly $1,036 and $1,107. GuruFocus's intrinsic value model estimated a fair value of $1,444.93, implying the stock traded at a discount of more than 30% even after the rally.
What's next for argenx
Detailed ALKIVIA data are expected at an upcoming medical meeting, and argenx plans to pursue regulatory filings in autoimmune myositis. The company is also evaluating efgartigimod in Sjögren's disease and systemic sclerosis, extending the FcRn platform beyond neuromuscular indications. Zai Lab holds an exclusive license to develop and commercialize VYVGART in Greater China and recruited Chinese patients into the trial.
For investors, the question is whether the myositis win can translate into sustained revenue growth. Vyvgart Hytrulo's subcutaneous delivery offers a convenience advantage over intravenous infusions for patients facing mobility and fatigue challenges, and each new indication adds incremental revenue on top of existing manufacturing and distribution infrastructure. With shares trading near a 52-week high of $1,002.16, the market has priced in much of the near-term upside, but longer-term models point to potential levels above $2,000 by 2030 if the pipeline delivers.
This article is for informational purposes only and does not constitute investment advice.
